At WiTii Pharmaceuticals, we are redefining how chronic diabetic wounds are treated; not by adding more signals, but by restoring the biological environment that allows healing to occur. Our work combines drug repurposing with mechanism-driven innovation to unlock new therapeutic potential from known compounds applied in entirely new ways.
Know Our Science
Request Information
$540K+ raised (Angel Funding)
Exclusive license UoW + Patent
Scientific POC established
In Vivo Animal Studies Commencing
Millions of diabetic patients suffer from chronic, non-healing wounds.
Existing therapies fail to consistently achieve durable healing.
Chronic wounds are not just slow to heal— they often fail to heal entirely, triggering a cascade of complications:
Americans living with Diabetes
(about 12% of the U.S. population )
People affected by DFUs in US annually (Jama Network,2023)
Amputations/ year linked to Diabetes
(American Diabetes Association)
~1 amputation every 3-4 minutes
$17B
Annual U.S. cost of diabetic limb complications exceeded all cancer types
Diabetic foot ulcers are not just wounds—they are the starting point of nearly 85% of diabetes-related amputations. With early detection and proper care, most complications can be prevented.
While the clinical consequences of diabetic foot ulcers are severe, their economic impact is equally striking.
Most amputations begin with wounds that fail to heal, even when standard therapies are applied—and the consequences extend far beyond the wound itself:
A Precision Mechanism-Driven Therapy
WiTii Pharmaceuticals is developing WiT-001, a small-molecule Cathepsin K inhibitor designed to restore the natural healing environment in diabetic wounds.
Key Advantages:
Breaking the Protease Barrier to Restore Healing
WiTii’s lead candidate, WiT‑001, is a first-in-class, locally delivered therapy designed to address a root cause of chronic wound failure: Excess protease activity that disrupts the body’s ability to heal
In chronic diabetic wounds, CatK a master protease become overactive: breaking down the tissue and structure needed for healing & healing stalls due to a destructive molecular environment.
WiTii’s therapy uses local topical delivery to deliver the drug directly to the wound bed:
Once the protease barrier is removed, the body’s natural healing sequence resumes.
WiT-001 – Cathepsin K Inhibitor for treating Diabetic Foot Ulcers
| Stage | Status | Next Milestone | Timeline |
|---|---|---|---|
| Formulation Development | Completed | Final optimization & stability ongoing | Q2 2026 |
| API Manufacturing Studies | Ongoing | Scale-up & GMP-grade production | Q2–Q3 2026 |
| Preclinical (Animal Studies) | Protocols in Development | Initiate IND-enabling studies | June 2026 |
Note: This capital-efficient path leverages existing safety and toxicology data from the original molecule to accelerate development.
Led by Scientific Innovation & Execution
Anand Shukla
CEO & Founder
Focused and results-driven pharmaceutical executive with extensive experience in the development and commercialization of branded and generic pharmaceutical products. He has a proven track record of building and scaling organizations from the ground up, as well as within established Fortune 500 companies. Anand brings broad expertise across all phases of the pharmaceutical development cycle — from concept to commercialization — and has consistently exceeded management and board expectations through strong execution and strategic partnerships.
Fortune 500 experience
Built & scaled teams
Concept to commercialization
Dr. Sreejayan (Sree) Nair
CSO & Co-Founder
Chair of the Division of Pharmaceutical Sciences at the University of Wyoming, Dr. Sree directs the Biomedical Sciences Graduate Program and mentors at the Wyoming Sensory Biology Center. A distinguished professor of Pharmacology, he has authored over 100 peer-reviewed papers, holds three U.S. patents, and has secured funding for 30 grants. His groundbreaking research on Cathepsin K inhibitors forms the scientific foundation of WiTii Pharmaceuticals — he is the inventor of the method-of-use patent for inhibiting Cathepsin K in diabetic wound healing, the core IP protecting WiT-001.
100+ peer-reviewed papers
3 U.S. patents
30 grants secured
Inventor — WiT-001 core IP
We are actively building a high-caliber group of advisors with deep expertise across the key disciplines required to advance WiT-001 to IND and beyond.
Wound Care
Clinical Development
Regulatory Strategy
CMC & Formulation
Know Our Team
Diabetic foot ulcers (DFUs) represent a large, growing, and underserved global market driven by rising diabetes prevalence, high treatment costs, and persistent gaps in clinical outcomes.
537M+
People living with diabetes globally
IDF Diabetes Atlas, 2021
1 in 3
Will develop a diabetic foot ulcer
Over their lifetime
~20%
Progress to amputation
Of all diabetic foot ulcer cases
~10%
Mortality within 1 year
Following major amputation
A rapidly expanding market driven by rising diabetes prevalence and persistent clinical gaps
The DFU Treatment Market is projected to grow steadily over the next decade:
CAGR 6.44% · North America share 38.88% (2025) · Forecast period 2026–2034
Fortune Buisness Insights 2025
High Cost Burden
$3K – $17K+
Cost per wound episode
Driven by hospitalizations, surgery, and long-term care
Treatment Gap Persists
Outcomes Remain Inconsistent
Healing failure continues despite multiple available therapies
Innovation Opportunity
Clear Need for Better Solutions
Opportunity for therapies that improve healing reliability and outcomes
The challenge is not the absence of treatment but the failure to restore the biology of healing. Despite its scale, outcomes remain inconsistent creating a clear opportunity for therapies that improve the reliability of healing, not just the availability of treatments.
WiTii addresses this gap through a mechanism-driven, repurposing-based approach designed to restore the biological conditions required for healing to occur.
WiTii’s platform is supported by strong intellectual property and institutional backing:
Built on science. Proven through execution. Designed for real-world impact.
We are advancing a differentiated, mechanism-driven approach to chronic wound healing.
Additional information is available through direct engagement.
Request Information
Contact Us
Great! We’ve received your information.
We couldn’t process your submission. Please retry